Propofol Manufacturing Plant Project Report 2026: Cost Analysis, ROI, and Feasibility Insights

The benchmark plant capacity is 20 to 100 metric tons per year of pharmaceutical-grade propofol.

The global propofol market is valued at around USD 1.0 billion to USD 1.6 billion, with a projected CAGR of around 4.0% to 5.0%.

General anesthesia accounts for 45% to 55% of demand, ICU sedation accounts for 25% to 30%, and procedural sedation makes up 15% to 20% of demand. Monitored anesthesia care and other uses constitute the remaining 5% to 10%.

The process relies on the acid-catalyzed isopropylation of phenol with propylene at approximately 200 to 300°C to form 2,6-diisopropylphenol, followed by purification through high-purity distillation. Key process inputs include phenol and propylene, while the reaction produces propofol as the main product.

Phenol and propylene are the key raw material requirements and together represent around 65% to 80% of total raw material costs. Other costs include catalysts, process aids, purification materials, and packaging inputs.

The alkylation reactor and the high-purity distillation train represent 45% to 55% of the total propofol plant setup cost.

Production costs are primarily driven by purchased phenol, which represents approximately 40% to 50% of variable operating expenses. Energy for alkylation, distillation, and high-purity finishing also drives costs, accounting for about 15% to 20% of OPEX. Other factors include propylene prices, process yield, maintenance, quality testing, waste treatment, and GMP compliance.

Active ingredient and generic production is concentrated in Asia, particularly China and India. North America and Europe are major regions for finished propofol emulsion production.

Available specifications include injectable grade and GMP-certified injectable-purity active ingredient. Pharmaceutical-grade propofol is controlled for assay, purity, related substances, identity, residual solvents, and other applicable quality parameters.

Manufacturing requires compliance with GMP standards and applicable drug master file or equivalent regulatory registrations. Manufacturers supplying regulated markets may also need to meet FDA or EMA requirements, maintain validated analytical methods and batch records, comply with quality and sterility controls for injectable products, and undergo regulatory inspections.